ORPHAN DRUGS IN FRANCE: KEY MARKET ACCESS INCENTIVES

被引：0
|
作者：
Mennezein, L. [1 ]
Avot, D. [1 ]
Laigle, V [2 ]
机构：
[1] MSD France, Courbevoie, France
[2] MSD Vaccins, Lyon, France
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.943
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY116
引用
收藏
页码：A565 / A565
页数：1
相关论文
共 50 条
  • [31] Analysis of patient access to orphan drugs in Turkey
    Güvenç Koçkaya
    Sibel Atalay
    Gülpembe Oğuzhan
    Mustafa Kurnaz
    Selin Ökçün
    Çiğdem Sar Gedik
    Mete Şaylan
    Nazlı Şencan
    Orphanet Journal of Rare Diseases, 16
  • [32] MARKET UPTAKE OF ORPHAN DRUGS - A EUROPEAN ANALYSIS
    Picavet, E.
    Cassiman, D.
    Simoens, S.
    VALUE IN HEALTH, 2011, 14 (07) : A341 - A341
  • [33] Analysis of patient access to orphan drugs in Turkey
    Kockaya, Guvenc
    Atalay, Sibel
    Oguzhan, Gulpembe
    Kurnaz, Mustafa
    Okcun, Selin
    Sar Gedik, Cigdem
    Saylan, Mete
    Sencan, Nazli
    ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)
  • [34] Orphan drugs: pricing, reimbursement and patient access
    Barak, Adam
    Nandi, Jyoti Shankar
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND HEALTHCARE MARKETING, 2011, 5 (04) : 299 - 317
  • [35] Market uptake of orphan drugs - a European analysis
    Picavet, E.
    Annemans, L.
    Cleemput, I.
    Cassiman, D.
    Simoens, S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (06) : 664 - 667
  • [36] ACCESS TO ORPHAN DRUGS IN FRANCE: THE CASE OF SIKLOS FOR THE TREATMENT OF SICKLE CELL SYNDROME BEFORE THE COUNCIL OF STATE
    Murteira, S.
    El Hammi, E.
    Kornfeld, A.
    Toumi, M.
    VALUE IN HEALTH, 2014, 17 (07) : A453 - A453
  • [37] HTA ASESSMENT COMPARISON OF ORPHAN DRUGS IN FRANCE AND GERMANY
    Remuzat, C.
    Mzoughi, O.
    Rodrigues, J.
    Korchagina, D.
    Toumi, M.
    VALUE IN HEALTH, 2014, 17 (03) : A236 - A237
  • [38] Determinants of orphan drugs prices in France: a regression analysis
    Daria Korchagina
    Aurelie Millier
    Anne-Lise Vataire
    Samuel Aballea
    Bruno Falissard
    Mondher Toumi
    Orphanet Journal of Rare Diseases, 12
  • [39] ORPHAN DRUGS: WHAT FACTORS IMPACT THE PRICE IN FRANCE?
    De Joannis, P. E.
    Borget, I
    VALUE IN HEALTH, 2019, 22 : S784 - S785
  • [40] PRICE LIFE CYCLE MANAGEMENT OF ORPHAN DRUGS IN FRANCE
    Lebreton, C.
    Avot, D.
    Morand, F.
    Laigle, V
    Troubat, A.
    VALUE IN HEALTH, 2017, 20 (09) : A660 - A660
12345